In recent years, several preclinical and clinical studies have explored the efficacy of using the mechano-therapeutic approach in cancer; promising outcomes, including those of drugs targeting CTGF, TGF-β signaling, and LOX-mediated matrix stiffening, have been achieved [44]. The gene discussed is TGFB1; the disease is cancer.